AZ initiate trials for using diabetes drug in kidney disease and heart failure

AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga with the aim of exploring its potential beyond the drug’s approved diabetes indication. AZ have initiated two randomised, placebo-controlled Phase IIIb outcome trials assessing Forxiga in the management of chronic kidney disease and chronic heart failure, within participants with and without type-2 diabetes. The

Continue Reading

NICE recommends PTC Therapeutics Duchenne muscular dystrophy treatment

PTC Therapeutics has announced that NICE has issued final guidance recommending Translarna for ambulatory patients aged five and over with nonsense mutation Duchenne muscular dystrophy in connection with a managed access agreement with NHS England. Duchenne muscular dystrophy, a rare genetic disease that primarily affects males, is a progressive muscular disorder caused by the lack

Continue Reading